Ironwood Pharmaceuticals, Inc. (IRWD)

NMS – Цена в реальном времени. Валюта: USD

4.38

+0.07 (1.75%)

Рынок открыт: Aug 12, 2026, 1:34 PM EDT

4.31

+0.01 (0.23%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

07.08.2026

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

06.08.2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

06.08.2026

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook.

06.08.2026

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.

06.08.2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. “Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profit.

Ironwood Pharmaceuticals, Inc. (IRWD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Видео

No Data

Пресс-релизы

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Search stocks

Ironwood Pharmaceuticals, Inc. (IRWD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Видео

No Data

Пресс-релизы

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results